Q-omics provides the consensus-scored SNHG25 profile across patient tissues and cancer cell-line models. SNHG25 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNHG25 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SNHG25 RNA expression shows 16,617 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where SNHG25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG25 survival associations across molecular data types. SNHG25 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG25 RNA expression–survival associations across cancer types. High SNHG25 expression shows unfavorable associations in KIRC, ACC, LAML, PRAD and KICH, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNHG25 RNA expression.
This table summarizes SNHG25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG25 shows higher tumor expression in KIRC, COAD, BLCA, LIHC, HNSC and UCEC. The KIRC box plot shows higher SNHG25 RNA expression in tumor versus normal tissue (log2 FC = +1.200, t-test p < 0.001).
This table shows molecular features associated with SNHG25 in patient tissues and cancer cell lines. In patient samples, SNHG25 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
